5 completed, 1 active not recruiting. 6 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 6 | Completed 5, Active not recruiting 1 |
Follow Intra-abdominal Infection: new trials by email Literature Review of Intra-abdominal Infection trials Research Report on Intra-abdominal Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The PASTDUe Nutrition Ecosystem Project (PASTDUe) Nutrition Ecosystem pathway, Comparator - Diet, Healthy, Food | Phase 4 | Active not recruiting | Duke University | 300 | 2022-04-25 | 2026-04-23 |
| Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults Zavicefta, Ceftazidime-Avibactam, Best Available Treatment - Urinary Tract Infection, Acute Pyelonephritis | Phase 4 | Completed | Pfizer | 60 | 2021-08-26 | 2024-10-21 |
| A Study To Determine The Efficacy And Safety Of Tigecycline Compared With Imipenem/Cliastatin to Treat Complicated Intra-Abdominal Infection Tigecycline, Imipenem/cilastatin - Intra-abdominal Infection | Phase 4 | Completed | Pfizer | 470 | 2012-11-01 | 2018-04-09 |
| A Comparative Study of Ampicillin/Sulbactam Versus Moxifloxacin in the Treatment of Complicated Intra-abdominal Infections moxifloxacin, ampicillin/sulbactam - Intra-abdominal Infection | Phase 4 | Completed | Kaohsiung Medical University Chung-Ho Memorial Hospital | 100 | 2009-01-01 | 2011-08-02 |
| T.E.A. Study Three Days Ertapenem Versus Three Days Ampicillin- Sulbactam Ertapenem, Ampicillin-Sulbactam - Intra-Abdominal Infection | Phase 4 | Completed | University of Bologna | 142 | 2008-01-01 | 2011-08-18 |
| Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection (cIAI) tigecycline, ceftriaxone plus metronidazole - Appendicitis, Cholecystitis | Phase 4 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 473 | 2005-10-01 | 2013-02-25 |
Intraabdominal Infections (6) · Abdominal Abscess (1) · Abdominal Injuries (1) · Abscess (1) · Appendicitis (1) · Bacteremia (1) · Cholecystitis (1) · Diverticulitis (1) · Healthcare-Associated Pneumonia (1) · Peritonitis (1) · Pneumonia, Ventilator-Associated (1) · Sepsis (1) · Urinary Tract Infections (1)
Infections (6) · Inflammation (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Systemic Inflammatory Response Syndrome (2) · Bacterial Infections (1) · Bacterial Infections and Mycoses (1) · Biliary Tract Diseases (1) · Cecal Diseases (1) · Cross Infection (1) · Digestive System Diseases (1) · Disease Attributes (1) · Diverticular Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1)
Tigecycline (2) · sultamicillin (2) · Ceftriaxone (1) · Cilastatin, Imipenem Drug Combination (1) · Ertapenem (1) · Metronidazole (1) · Moxifloxacin (1) · avibactam, ceftazidime drug combination (1)
Pfizer (2) · Duke University (1) · Kaohsiung Medical University Chung-Ho Memorial Hospital (1) · University of Bologna (1) · Wyeth is now a wholly owned subsidiary of Pfizer (1)
China (3) · Italy (2) · Taiwan (2) · Australia (1) · Denmark (1) · Finland (1) · France (1) · Germany (1) · Greece (1) · Hong Kong (1) · India (1) · Philippines (1) · Portugal (1) · Saudi Arabia (1) · South Africa (1)
Antonio Daniele Pinna, MD (1) · Cristina Puggioli, MD (1) · Fausto Catena, MD PhD (1) · Giorgio Ercolani, MD (1) · Luca Ansaloni, MD (1) · Paul Wischmeyer (1) · Salomone Di Saverio, M.D. (1)
PMID 21501482, PMID 22439781, PMID 23631512, PMID 30584308, PMID 42829121